FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib

This study is currently Recruiting

July 2011 By M.D. Anderson Cancer Center

First Recieved on November 17, 2009

Last Updated on July 20, 2011

Sponsor: M.D. Anderson Cancer Center
Collaborators:
Information provided by: M.D. Anderson Cancer Center
Identifier: NCT01016028

Purpose

The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.

Study Type: Observational
Study Design: Observational Model: Case-Only, Time Perspective: Prospective

Eligibility

Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: 1. Patients >= 18 years old. 2. Patients must be fluent with the English language. 3. Patients must be on chemotherapy regimes with any of the study drugs: cisplatin, oxaliplatin, taxanes and/or bortezomib. Exclusion Criteria: 1. Significant cognitive impairment as determined by the trained research staff 2. Chronic alcoholism or substance abuse 3. Diagnosis of severe depression

Investigators

  • Investigator: Sonika Agarwal, MD - Study Chair - UT MD Anderson Cancer Center

Locations

  • UT MD Anderson Cancer Center

    Houston, Texas 77030 United States

Conditions related to this trial:

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.